Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 7/20 | 0.82 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.82 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 9/20 | 0.76 |
| ▸ | THRB | P10828 | 9/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.76 |
| ▸ | BLM | P54132 | 8/20 | 0.76 |
| ▸ | RECQL | P46063 | 7/20 | 0.76 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | USP2 | O75604 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.76 |
| ▸ | TOP2A | P11388 | 4/20 | 0.76 |
| ▸ | HTT | P42858 | 4/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015224 | 1.00 | S100A4 (0.82) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL30260668 | 1.00 | S100A4 (0.82) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL27337885 | 1.00 | S100A4 (0.82) | S100A4PAX8HSP90AA1MEN1THRB | |
| Hydrochloric Acid SCHEMBL15646425 | 0.99 | S100A4 (0.81) | S100A4PAX8HSP90AA1MEN1THRB | |
| Hydrochloric Acid SCHEMBL22589715 | 0.99 | S100A4 (0.81) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL10608078 | 0.94 | S100A4 (0.76) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL7899430 | 0.94 | S100A4 (0.84) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL7801035 | 0.91 | S100A4 (0.83) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL7805227 | 0.91 | S100A4 (0.83) | S100A4PAX8HSP90AA1MEN1THRB | |
| SCHEMBL27509581 | 0.91 | S100A4 (0.85) | S100A4PAX8HSP90AA1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12625139-B2 | Methods for modulation of acetyltransferase activity and applications thereof including treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2026-05-12 | — | — | US | claimed |
| US-20220196660-A1 | Methods for Modulation of Acetyltransferase Activity and Applications Thereof Including Treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | US | claimed |
| US-20210361741-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | XEQUEL BIO, INC. | 2021-11-25 | — | — | US | claimed |
| EP-3849528-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | Firststring Research, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| WO-2020219598-A1 | METHODS FOR MODULATION OF ACETYLTRANSFERASE ACTIVITY AND APPLICATIONS THEREOF INCLUDING TREATMENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-29 | — | — | WO | claimed |
| WO-2020056144-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | FIRSTSTRING RESEARCH, INC. (US) | 2020-03-19 | — | — | WO | claimed |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2019-03-21 | — | — | US | claimed |
| US-7928202-B2 | Targeting ABCB5 for cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-04-19 | — | — | US | claimed |
| WO-2010065711-A1 | AN ABCB5 EPITOPE AND ANTIBODIES THERETO FOR THE TREATMENT OF CANCER | ADIMAB, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2155248-A1 | TARGETING ABCB5 FOR CANCER THERAPY | The Brigham and Women's Hospital, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | claimed |
| US-20090117117-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-05-07 | — | — | US | claimed |
| WO-2008127656-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080188480-A1 | Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier | CEDARS-SINAI MEDICAL CENTER (US) | 2008-08-07 | — | — | US | claimed |
| EP-1850852-A2 | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER | Cedars-Sinai Medical Center (US) | 2007-11-07 | — | — | EP | claimed |
| EP-1848717-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Topotarget A/S (DK) | 2007-10-31 | — | — | EP | claimed |
| WO-2006091542-A2 | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2006085219-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2006-08-17 | — | — | WO | claimed |
| US-4177264-A | ANITCARCINOGENIC AGENTS | SRI INTERNATIONAL (US) | 1979-12-04 | — | — | US | claimed |
| US-12625139-B2 | Methods for modulation of acetyltransferase activity and applications thereof including treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2026-05-12 | — | — | US | disclosed |
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| CN-118354788-A | Anti-glyco-MUC 4 antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4395810-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4396232-A1 | ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114177308-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4392056-A2 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY | Musc Foundation for Research Development (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240197906-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024129585-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199724-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2024-06-20 | — | — | US | disclosed |
| US-20240189405-A1 | DNA Monoclonal Antibodies Targeting Checkpoint Molecules | INOVIO PHARMACEUTICALS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4380604-A1 | ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4373477-A2 | METHODS AND USES OF USING ACTIVATORS OF NRF2 TO ENHANCE NATURAL KILLER CELLS AND/OR T CELL ACTIVITY AND/OR SURVIVAL | Proleukocyte AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| US-11993661-B2 | Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof | Eureka Therapeutics, Inc. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024102902-A1 | METHODS OF TREATING OR PREVENTING LIVER DISEASES OR DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158521-A1 | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-16 | — | — | US | disclosed |
| EP-4366764-A1 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | Codagenix Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-112384531-B | Binding molecules to BCMA and uses thereof | 诺华股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11963938-B2 | Use of short chain fatty acids in cancer prevention | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024077232-A2 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076964-A1 | PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240108651-A1 | Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use | THOMAS JEFFERSON UNIVERSITY | 2024-04-04 | — | — | US | disclosed |
| US-20240108766-A1 | LRRC15 ANTIBODIES AND CONJUGATES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024059621-A2 | T-CELL RECEPTORS AND COMPOSITIONS THEREOF FOR TARGETING MUTANT RAS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117653725-A | anti-CCR 8 antibody therapy: biomarkers and combination therapies | 拜耳公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024050505-A2 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 AND PHOSPHOINOSITIDE 3-KINASE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-117651551-A | Use and method of using Nrf2 activators to enhance natural killer and/or T cell activity and/or survival | 成白血球细胞公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11919959-B2 | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-03-05 | — | — | US | disclosed |
| US-20240050596-A1 | DYE AGGREGATES-CONTAINING NANOPARTICLES AND USES THEREOF | UNIV TEXAS (US) | 2024-02-15 | — | — | US | disclosed |
| US-11896654-B2 | DNA monoclonal antibodies targeting checkpoint molecules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4308595-A1 | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13RALPHA2 AND METHODS OF USE IN CANCER THERAPEUTICS | The Wistar Institute of Anatomy and Biology (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015916-A2 | 4'-ALKYNE-2'-DEOXYCYTIDINE-BASED COMPOUNDS AND ANTI-CANCER USES THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-117396498-A | IL13Rα2-targeting DNA-encoded bispecific antibodies and methods of use in cancer treatment | 威斯塔解剖学和生物学研究所 | 2024-01-12 | — | — | CN | disclosed |
| WO-2024011220-A1 | POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING TISSUE DYSFUNCTION CAUSED BY TOXIC INSULTS | UNIVERSITY OF ROCHESTER (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | disclosed |
| EP-4301782-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-111886257-B | Anti-renalase antibodies for the treatment and prevention of diseases and conditions | 耶鲁大学 | 2024-01-05 | — | — | CN | disclosed |
| US-11857624-B2 | Cancer therapeutic methods utilizing OPCML fragment | PAPYRUS THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023235811-A2 | COMBINATION OF DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPEUTICS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4281477-A2 | LRRC15 ANTIBODIES AND CONJUGATES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-11-29 | — | — | EP | disclosed |
| CN-117083303-A | Binding molecules with high affinity and/or specificity and methods of making and using the same | 阿拉码生物科学股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023220734-A2 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215796-A2 | SILOXANE-BASED LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357435-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | PASTEUR INSTITUT (FR) | 2023-11-09 | — | — | US | disclosed |
| EP-4271482-A2 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | Alamar Biosciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116963771-A | Desmosomal protein 2-directed Chimeric Antigen Receptor (CAR) constructs and methods of use | 托马斯杰弗逊大学 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023205689-A2 | DEOPTIMIZED INFLUENZA VIRUSES AND METHODS OF TREATING CANCER | CODAGENIX INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023201301-A2 | BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023196953-A2 | COMBINATIONS OF BISPECIFIC T CELL ENGAGERS AND METHODS OF USE THEREOF | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196957-A2 | BISPECIFIC T CELL ENGAGERS TARGETING TUMOR ANTIGENS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196954-A2 | BISPECIFIC BINDING MOLECULES THAT TARGET FSHR AND CD3 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4255484-A1 | DESMOGLEIN 2-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND METHODS OF USE | Thomas Jefferson University (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11780934-B2 | Use of inhibitors of ADAM12 as adjuvants in tumor therapies | INSTITUT PASTEUR (FR) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192992-A2 | BISPECIFIC NATURAL KILLER ENGAGERS THAT TARGET SIGLEC-7 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192993-A2 | ANTIBODIES AGAINST HUMAN SIGLEC-7 AND USE THEREOF FOR IMMUNOTHERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192990-A2 | ANTIBODIES AGAINST HUMAN SIGLEC-9 AND USE THEREOF FOR IMMUNOTHERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-11759442-B2 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-19 | — | — | US | disclosed |
| CN-116745323-A | LRRC15 antibodies and conjugates thereof | 拜耳股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230277628-A1 | METHODS FOR PROMOTING ANTI-TUMOR IMMUNE RESPONSE IN A SUBJECT IN NEED THEREOF USING ENCAPSULATED INTERLEUKIN 12 | SPECTRUM PHARMACEUTICALS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277490-A1 | GLUTAMINE AS AN ANTICANCER THERAPY IN SOLID TUMORS | CEDARS-SINAI MEDICAL CENTER (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4232057-A2 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2023-08-30 | — | — | EP | disclosed |
| US-20230250178-A1 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-10 | — | — | US | disclosed |
| WO-2023147292-A2 | ANAPLASTIC LYMPHOMA KINASE ANTIBODIES AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230241167-A1 | Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2023-08-03 | — | — | US | disclosed |
| WO-2023144392-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2023-08-03 | — | — | WO | disclosed |
| US-11713352-B2 | Immunotoxin for treating cancer | UNIVERSITY OF ZÜRICH (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11712487-B2 | Composite embolization beads | RAIKA MEDICAL IMAGING INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713351-B2 | Immunotoxin for treating cancer | UNIVERSITY OF ZÜRICH (CH) | 2023-08-01 | — | — | US | disclosed |
| US-20230210916-A1 | Bacteriocin Production, Compositions and Methods of Use | ISOTHRIVE INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210989-A1 | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2023-07-06 | — | — | US | disclosed |
| WO-2023129848-A1 | BRAIN TARGETED NANOPARTICLES OR CONJUGATES AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-3410849-B1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | PASTEUR INSTITUT (FR) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023107920-A1 | ANISAMIDE-CONTAINING LIPIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-116249549-A | Bispecific combination therapies for the treatment of proliferative diseases and autoimmune disorders | 诺华股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116234825-A | CCR8 antibodies for therapeutic applications | 拜耳公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230159896-A1 | MULTI-LINEAGE CARDIOVASCULAR MICROFLUIDIC ORGAN-CHIP | CEDARS-SINAI MEDICAL CENTER (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3811940-B1 | SUBSTITUTED 4,5'-BITHIAZOLES AS INHIBITORS OF THE HUMAN DNA TOPOISOMERASE II | KEMIJSKI INST (SI) | 2023-05-10 | — | — | EP | disclosed |
| CN-116096395-A | Sulfated peptides for production of chemokine receptor antibodies | 拜耳公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096750-A | anti-CCR 8 antibody therapy: biomarkers and combination therapies | 拜耳公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096749-A | CCR8 antibodies and uses thereof | 拜耳公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096748-A | Chemokine receptor antibodies that bind to sulfated TRD motifs | 拜耳公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4172204-A2 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171601-A2 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172202-A2 | ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171649-A2 | USE OF CAVEOLIN-1 SCAFFOLDING DOMAIN PEPTIDES FOR TREATING DISEASE AND DISORDERS | Musc Foundation for Research Development (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172201-A2 | CHEMOKINE RECEPTOR ANTIBODIES BINDING SULFATED TRD MOTIFS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171602-A2 | CCR8 ANTIBODIES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230116885-A1 | METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT | MYRIAD GENETICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023039399-A2 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023034571-A1 | ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034569-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230071196-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230063151-A1 | CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY | WISTAR INST (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | disclosed |
| US-11590202-B2 | Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230048360-A1 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | Eureka Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| WO-2023014863-A1 | ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| EP-4126241-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-11566075-B2 | Antibodies and related molecules and uses thereof | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20230025360-A1 | PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS | MUSC FOUND FOR RES DEV (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023283593-A1 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | CODAGENIX INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4114860-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20230000823-A1 | Compounds and Methods for the Treatment of Acute Myelogenous Leukemia | UNIVERSITY OF ROCHESTER | 2023-01-05 | — | — | US | disclosed |
| WO-2023278893-A1 | ADOPTIVE IMMUNOTHERAPY COMPOSITIONS AND METHODS OF TRACKING | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| CN-115350171-A | Use of short chain fatty acids in cancer prevention | 坦普尔大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-115315446-A | anti-sugar-CD 44 antibodies and uses thereof | GO医疗股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220348684-A1 | Anti-Renalase Antibodies for the Treatment and Prevention of Diseases and Disorders | YALE UNIVERSITY | 2022-11-03 | — | — | US | disclosed |
| WO-2022221181-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220211645-A1 | Maximizing Distribution and Minimizing Washout of Injectates in Bone and Method for Enhanced Aspirate Extraction | YALE UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| WO-2022147463-A2 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | ALAMAR BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11370846-B2 | Compositions and methods to regulate Renalase in the treatment of cancer | YALE UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220196660-A1 | Methods for Modulation of Acetyltransferase Activity and Applications Thereof Including Treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220185910-A1 | CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | Eureka Therapeutics, Inc. | 2022-06-16 | — | — | US | disclosed |
| WO-2022120010-A1 | DESMOGLEIN 2-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND METHODS OF USE | THOMAS JEFFERSON UNIVERSITY (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-4003333-A1 | MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF | The Wistar Institute for Anatomy and Biology (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003421-A1 | MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF | The Wistar Institute of Anatomy and Biology (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11345747-B2 | Methods and compositions for the treatment of diseases and disorders | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220160464-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3996736-A1 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY | Musc Foundation for Research Development (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220142978-A1 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | UNIV TEMPLE (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3986437-A1 | COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATION | Musc Foundation for Research Development (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3972993-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220088190-A1 | Compositions and Methods for Targeting Mutant RAS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-03-24 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3247727-B1 | INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS | CANCER RESEARCH TECH LTD (GB) | 2022-03-23 | — | — | EP | disclosed |
| EP-3965635-A2 | MAXIMIZING DISTRIBUTION AND MINIMIZING WASHOUT OF INJECTATES IN BONE AND METHOD FOR ENHANCED ASPIRATE EXTRACTION | Yale University (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220073614-A1 | DNA MONOCLONAL ANTIBODIES TARGETING PD-1 FOR THE TREATMENT AND PREVENTION OF CANCER | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2022-03-10 | — | — | US | disclosed |
| US-11246893-B2 | Bacteriocin production, compositions and methods of use | ISOTHRIVE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3946489-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022026867-A1 | GLUTAMINE AS AN ANTICANCER THERAPY IN SOLID TUMORS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220025349-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-20220008369-A1 | Use of Short Chain Fatty Acids in Cancer Prevention | UNIV TEMPLE (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2022006064-A2 | USE OF CAVEOLIN-1 SCAFFOLDING DOMAIN PEPTIDES FOR TREATING DISEASE AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-01-06 | — | — | WO | disclosed |
| CN-109562189-B | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021260210-A2 | ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260209-A2 | CCR8 ANTIBODIES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260208-A2 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260206-A2 | CHEMOKINE RECEPTOR ANTIBODIES BINDING SULFATED TRD MOTIFS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| US-20210387020-A1 | IMMUNE MODULATORS IN COMBINATION WITH RADIATION TREATMENT FOR ADVANCED PANCREATIC CANCER | UNIV ROCHESTER (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3917548-A1 | DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS | The Wistar Institute of Anatomy and Biology (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3914270-A1 | COMPOSITIONS AND METHODS FOR TARGETING MUTANT RAS | The Trustees of the University of Pennsylvania (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210361741-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | XEQUEL BIO, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210355235-A1 | Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies | UNIV YALE (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3908299-A1 | DNA MONOCLONAL ANTIBODIES TARGETING PD-1 FOR THE TREATMENT AND PREVENTION OF CANCER | The Wistar Institute of Anatomy and Biology (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-113631172-A | Compositions and methods for targeting mutant RAS | 宾夕法尼亚大学理事会 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021222724-A1 | MULTI-LINEAGE CARDIOVASCULAR MICROFLUIDIC ORGAN-CHIP | CEDARS-SINAI MEDICAL CENTER (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210340531-A1 | Compositions and Methods for Inhibiting Intermediate Filament Tetramerization | YALE UNIVERSITY | 2021-11-04 | — | — | US | disclosed |
| US-20210338614-A1 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-04 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-113543800-A | DNA monoclonal antibodies targeting PD-1 for treatment and prevention of cancer | 威斯塔解剖学和生物学研究所 | 2021-10-22 | — | — | CN | disclosed |
| US-20210317203-A1 | AN IMMUNOTOXIN FOR TREATING CANCER | UNIVERSITY OF ZURICH (CH) | 2021-10-14 | — | — | US | disclosed |
| EP-3891181-A2 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | Novartis AG (CH) | 2021-10-13 | — | — | EP | disclosed |
| EP-3886887-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The Children's Hospital Of Philadelphia (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113474458-A | DNA-encoded bispecific T-cell linkers that target cancer antigens and methods of use in cancer therapy | 威斯塔解剖学和生物学研究所 | 2021-10-01 | — | — | CN | disclosed |
| WO-2021195513-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| CN-113396161-A | Binding molecules to CD3 and uses thereof | 诺华股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021178896-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210277117-A1 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. | 2021-09-09 | — | — | US | disclosed |
| CN-106659772-B | Compositions and methods for modulating renalase in the treatment of diseases and disorders | 耶鲁大学 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021163072-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-08-19 | — | — | WO | disclosed |
| US-11090309-B2 | Anti-thrombotic agents and methods of use thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021152186-A2 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155097-A1 | CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3431103-B1 | TARGETING ABCB5 FOR CANCER THERAPY | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3849528-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | Firststring Research, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11065217-B2 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210205364-A1 | LONG LIVED ENGINEERED T CELLS FOR ADOPTIVE CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-08 | — | — | US | disclosed |
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112996816-A | anti-sugar-MUC 1 antibodies and uses thereof | GO医疗股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112969451-A | Nanoparticle formulations and methods using alpha connexin C-terminal peptides | 福斯特斯特林研究公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-20210154335-A1 | DYE AGGREGATES-CONTAINING NANOPARTICLES AND USES THEREOF | UNIV TEXAS (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2021-05-13 | — | — | US | disclosed |
| EP-3814384-A1 | ANTI-GLYC0-MUC1 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3811940-A1 | SUBSTITUTED 4,5'-BITHIAZOLES AS INHIBITORS OF THE HUMAN DNA TOPOISOMERASE II | Kemijski Institut (SI) | 2021-04-28 | — | — | EP | disclosed |
| EP-3806904-A1 | CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210107992-A1 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | Eureka Therapeutics, Inc. | 2021-04-15 | — | — | US | disclosed |
| EP-3802611-A2 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3793575-A1 | LONG LIVED CHIMERIC ANTIGEN RECEPTOR (CAR) EXPRESSING T CELLS FOR CANCER THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20210070867-A1 | Inhibitors of the Interaction Between CLEC14A and Multimerin-2 for Inhibition of Angiogenesis | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| CN-112384531-A | Binding molecules against BCMA and uses thereof | 诺华股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3774910-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210040203-A1 | IMMUNOTOXIN FOR TREATING CANCER | UNIVERSITY OF ZURICH (CH) | 2021-02-11 | — | — | US | disclosed |
| WO-2021022107-A1 | MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022113-A1 | MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210024652-A1 | Compositions and Methods to Regulate Renalase in the Treatment of Cancer | YALE UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
| WO-2021007094-A1 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210008173-A1 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2021-01-14 | — | — | US | disclosed |
| CN-112204052-A | Trispecific binding molecules for cancer and uses thereof | 诺华股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3626273-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020257405-A1 | COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATION | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2020-12-24 | — | — | WO | disclosed |
| US-10858429-B2 | Methods for treating cancer using an immunotoxin | UNIVERSITY OF ZURICH (CH) | 2020-12-08 | — | — | US | disclosed |
| WO-2020236797-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236795-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236792-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| CN-111971071-A | CTLA-4-targeting DNA monoclonal antibodies for the treatment and prevention of cancer | 威斯塔解剖学和生物学研究所 | 2020-11-20 | — | — | CN | disclosed |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200353080-A1 | CANCER METHODS | GABRA HANI (GB) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227558-A2 | MAXIMIZING DISTRIBUTION AND MINIMIZING WASHOUT OF INJECTATES IN BONE AND METHOD FOR ENHANCED ASPIRATE EXTRACTION | YALE UNIVERSITY (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3732204-A1 | ANTI-RENALASE ANTIBODIES FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS | Yale University (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111886257-A | Anti-renalase antibodies for the treatment and prevention of diseases and disorders | 耶鲁大学 | 2020-11-03 | — | — | CN | disclosed |
| US-20200340031-A1 | Methods for Measuring Renalase | YALE UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| WO-2020219598-A1 | METHODS FOR MODULATION OF ACETYLTRANSFERASE ACTIVITY AND APPLICATIONS THEREOF INCLUDING TREATMENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10808031-B2 | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-10-20 | — | — | US | disclosed |
| EP-3212668-B1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200316233-A1 | RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2020-10-08 | — | — | US | disclosed |
| EP-3717019-A2 | RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF | Board of Regents of the University of Nebraska (US) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020198468-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3713962-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENS AND USES THEREOF | Novartis AG (CH) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020191356-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | GONCALVES MARCUS (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200283855-A1 | METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT | MYRIAD GENETICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283525-A1 | DNA MONOCLONAL ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2020-09-10 | — | — | US | disclosed |
| EP-3700936-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262930-A1 | ANTI-YKL40 ANTIBODIES AND METHODS OF USE | UNIV YALE (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3691694-A1 | DNA MONOCLONAL ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER | The Wistar Institute Of Anatomy And Biology (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020160090-A1 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEREOF | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160310-A1 | DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020154617-A1 | COMPOSITIONS AND METHODS FOR TARGETING MUTANT RAS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-3684819-A1 | ANTI-YKL40 ANTIBODIES AND METHODS OF USE | Yale University (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10722578-B2 | Methods and compositions for treating neuroblastoma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020146865-A1 | DNA MONOCLONAL ANTIBODIES TARGETING PD-1 FOR THE TREATMENT AND PREVENTION OF CANCER | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-2219619-B1 | DISULFIDE CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2020-07-09 | — | — | US | disclosed |
| EP-3383909-B1 | ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3458102-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020112991-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200166510-A1 | FLOW CYTOMETRY-BASED PLATFORM FOR THE DETECTION, ENUMERATION, AND ISOLATION OF DISSEMINATED TUMOR CELLS IN BONE MARROW ASPIRATES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-05-28 | — | — | US | disclosed |
| US-10660955-B2 | Cancer methods | GABRA HANI (GB) | 2020-05-26 | — | — | US | disclosed |
| US-20200157199-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2020-05-21 | — | — | US | disclosed |
| EP-2717813-B1 | DRUG DELIVERY DEVICE EMPLOYING WICKING RELEASE WINDOW | AURITEC PHARMACEUTICALS (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200138988-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2020-05-07 | — | — | US | disclosed |
| US-20200138828-A1 | Anti-thrombotic Agents and Methods of Use Thereof | UNIV TEMPLE (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3645058-A1 | COMPOSITE EMBOLIZATION BEADS | The Regents of The University of California (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2020081929-A1 | IMMUNE MODULATORS IN COMBINATION WITH RADIATION TREATMENT FOR ADVANCED PANCREATIC CANCER | UNIVERSITY OF ROCHESTER (US) | 2020-04-23 | — | — | WO | disclosed |
| US-10618975-B2 | Antibody to Renalase | YALE UNIVERSITY (US) | 2020-04-14 | — | — | US | disclosed |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3626273-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2020056144-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | FIRSTSTRING RESEARCH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052692-A2 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200085912-A1 | Compositions and Methods for Treating Inflammation and Cancer | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-03-19 | — | — | US | disclosed |
| US-20200087400-A1 | CONSTRUCTS TARGETING PSA PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10583198-B2 | Dosing strategies for targeting EPCAM positive bladder cancer | VIVENTIA BIO INC. (CA) | 2020-03-10 | — | — | US | disclosed |
| EP-3615574-A1 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10576163-B2 | Methods of treatment for EpCAM positive bladder cancer | VIVENTIA BIO INC. (CA) | 2020-03-03 | — | — | US | disclosed |
| US-20200055905-A1 | Bacteriocin Production, Compositions and Methods of Use | ISOTHRIVE INC. | 2020-02-20 | — | — | US | disclosed |
| EP-3609519-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND CANCER | University of Maryland, Baltimore (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3598980-A2 | COMPOSITIONS AND METHODS TO REGULATE RENALASE IN THE TREATMENT OF DISEASES AND DISORDERS | Yale University (US) | 2020-01-29 | — | — | EP | disclosed |
| CN-110603447-A | Compositions and methods for treating cancer with anti-renalase antibodies and anti-PD 1 antibodies | 耶鲁大学 | 2019-12-20 | — | — | CN | disclosed |
| WO-2018200586-A9 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2019-11-28 | — | — | WO | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
| EP-3551168-A1 | IMMUNOMODULATORY COMPOUNDS | Lankenau Institute for Medical Research (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2019195535-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019186344-A1 | ANTI-CANCER AND DISINTEGRIN SCORPION VENOMS | INSTITUT PASTEUR DE TUNIS (TN) | 2019-10-03 | — | — | WO | disclosed |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3052525-B1 | ANTI-EPCAM ANTIBODIES AND METHODS OF USE | VIVENTIA BIO INC (CA) | 2019-07-24 | — | — | EP | disclosed |
| US-20190211111-A1 | Switchable antibody conjugate | Temple University--of the Commonwealth System of Higher Education | 2019-07-11 | — | — | US | disclosed |
| US-20190194355-A1 | Compositions and Methods to Regulate Renalase in the Treatment of Cancer | YALE UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-20190185532-A1 | INHIBITORS | UNIV BIRMINGHAM (GB) | 2019-06-20 | — | — | US | disclosed |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2019102456-A1 | IMMUNOTOXINS FOR TREATING CANCER | UNIVERSITY OF RIJEKA FACULTY OF MEDICINE (HR) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104075-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| US-20190160031-A1 | Use of Short Chain Fatty Acids in Cancer Prevention | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| EP-3487879-A2 | INHIBITORS OF THE MMRN2 INTERACTION WITH CLEC14A AND/OR CD93 | The University of Birmingham (GB) | 2019-05-29 | — | — | EP | disclosed |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-05-21 | — | — | US | disclosed |
| US-20190142920-A1 | DNA Monoclonal Antibodies Targeting Checkpoint Molecules | INOVIO PHARMACEUTICALS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190125796-A1 | PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-05-02 | — | — | US | disclosed |
| US-10273311-B2 | Compositions to regulate renalase in the treatment of diseases and disorders | YALE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2019070834-A1 | DNA MONOCLONAL ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER | WEINER DAVID (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019060675-A1 | ANTI-YKL40 ANTIBODIES AND METHODS OF USE | YALE UNIVERSITY (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-3458102-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITY DE STRASBOURG (FR) | 2019-03-26 | — | — | US | disclosed |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2019-03-21 | — | — | US | disclosed |
| US-20190085081-A1 | CHIMERIC ANTIGEN RECEPTOR | CANCER RESEARCH TECH LTD (GB) | 2019-03-21 | — | — | US | disclosed |
| US-20190085082-A1 | ANTIBODIES AND RELATED MOLECULES AND USES THEREOF | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10231941-B2 | Use of short chain fatty acids in cancer prevention | Temple University—Of The Commonwealth System of Higher Educaton (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3452107-A1 | DNA MONOCLONAL ANTIBODIES TARGETING CHECKPOINT MOLECULES | The Trustees of The University of Pennsylvania (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190031776-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2019-01-31 | — | — | US | disclosed |
| US-20190030306-A1 | DRUG DELIVERY DEVICE EMPLOYING WICKING RELEASE WINDOW | OAK CREST INSTITUTE OF SCIENCE | 2019-01-31 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3431103-A1 | TARGETING ABCB5 FOR CANCER THERAPY | The Brigham and Women's Hospital, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10181009-B2 | Methods and systems for predicting cancer outcome | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20190011433-A1 | CELL CO-CULTURE SYSTEMS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2019-01-10 | — | — | US | disclosed |
| WO-2019006099-A1 | COMPOSITE EMBOLIZATION BEADS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006445-A1 | ANTI-THROMBOTIC AGENTS AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20180362587-A1 | Compositions and Methods for Inhibiting CBP80 Binding to PGC1 Family of Co-Activators | UNIVERSITY OF ROCHESTER | 2018-12-20 | — | — | US | disclosed |
| WO-2018227050-A1 | FLOW CYTOMETRY-BASED PLATFORM FOR THE DETECTION, ENUMERATION, AND ISOLATION OF DISSEMINATED TUMOR CELLS IN BONE MARROW ASPIRATES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-3410849-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | Institut Pasteur (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-10143669-B2 | Use of short chain fatty acids in cancer prevention | Temple University—Of the Commonwealth System of Higher Education (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018200586-A1 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018191348-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-3383909-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3383910-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180282418-A1 | INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2018175673-A1 | METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF CANCER | THE ROCKEFELLER UNIVERSITY (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018165362-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-RENALASE ANTIBODIES AND ANTI-PD1 ANTIBODIES | YALE UNIVERSITY (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20180250418-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2018-09-06 | — | — | US | disclosed |
| WO-2018156886-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018154307-A1 | MODULATORS OF THE INTERACTION OF CD248 WITH ITS LIGAND MULTIMERIN 2 | THE UNIVERSITY OF BIRMINGHAM (GB) | 2018-08-30 | — | — | WO | disclosed |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180214399-A1 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | Temple University--of the Commonwealth System of Higher Education | 2018-08-02 | — | — | US | disclosed |
| WO-2018140687-A1 | USE OF SHORT CHAIN FATTY ACIDS FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-3133080-B1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2018-08-01 | — | — | EP | disclosed |
| US-20180208658-A1 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. | 2018-07-26 | — | — | US | disclosed |
| US-10022325-B2 | Compositions and methods for the treatment of cancer | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180185307-A1 | Use of Short Chain Fatty Acids in Cancer Prevention | Temple University--of the Commonwealth System of Higher Education | 2018-07-05 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011658-B2 | Constructs targeting AFP peptide/MHC complexes and uses thereof | Eureka Therapeutics, Inc. (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2018107027-A1 | IMMUNOMODULATORY COMPOUNDS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-2644205-B1 | Targeting ABCB5 for cancer therapy | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3313873-A2 | CONSTRUCTS TARGETING NY-ESO-1 PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180104356-A1 | METHODS OF TREATMENT FOR EPCAM POSITIVE BLADDER CANCER | VIVENTIA BIO INC. (CA) | 2018-04-19 | — | — | US | disclosed |
| US-20180104355-A1 | DOSING STRATEGIES FOR TARGETING EPCAM POSITIVE BLADDER CANCER | VIVENTIA BIO INC. (CA) | 2018-04-19 | — | — | US | disclosed |
| US-9937335-B2 | Drug delivery device employing wicking release window | OAK CREST INSTITUTE OF SCIENCE (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180079815-A1 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. | 2018-03-22 | — | — | US | disclosed |
| EP-3294328-A1 | CONSTRUCTS TARGETING HPV16-E7 PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2018035410-A1 | COMPOSITIONS AND METHODS OF TREATMENT USING EXPANDED-SIZE DNA ANALOGS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-3277314-A1 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2018020222-A2 | INHIBITORS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2018-02-01 | — | — | WO | disclosed |
| US-20180015163-A1 | CANCER METHODS | GABRA HANI (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180008565-A1 | Use of Short Chain Fatty Acids in Cancer Prevention | Temple University--of the Commonwealth System of Higher Education | 2018-01-11 | — | — | US | disclosed |
| US-20180009882-A1 | Methods and Compositions for the Treatment of Diseases and Disorders | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2018-01-11 | — | — | US | disclosed |
| US-9855342-B2 | Targeting ABCB5 for cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9850313-B2 | Cancer biomarkers and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| EP-3247396-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS | Lankenau Institute for Medical Research (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-3247342-A1 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-3247727-A2 | INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS | Cancer Research Technology Limited (GB) | 2017-11-29 | — | — | EP | disclosed |
| WO-2017201204-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9822182-B2 | Anti-EPCAM antibodies and methods of use | VIVENTIA BIO INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| WO-2017193094-A1 | DNA MONOCLONAL ANTIBODIES TARGETING CHECKPOINT MOLECULES | WEINER, DAVID (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017189965-A1 | PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170266166-A1 | Compositions and Methods to Inhibit Estrogen Receptor Beta for the Treatment of Renal Cell Carcinoma | UNIV ROCHESTER (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170240584-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2017-08-24 | — | — | US | disclosed |
| WO-2017134265-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | INSTITUT PASTEUR (FR) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226228-A1 | Compositions and Methods to Regulate Renalase in the Treatment of Diseases and Disorders | YALE UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| WO-2017099821-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CBP80 BINDING TO PGCI FAMILY OF CO-ACTIVATORS | UNIVERSITY OF ROCHESTER (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017095808-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017095805-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-2829283-B1 | Methods for treating cancer using an immunotoxin | UNIV ZUERICH (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9649378-B2 | Cancer methods | GABRA HANI (GB) | 2017-05-16 | — | — | US | disclosed |
| EP-3160493-A2 | COMPOSITIONS AND METHODS TO REGULATE RENALASE IN THE TREATMENT OF DISEASES AND DISORDERS | Yale University (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9624257-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2017-04-18 | — | — | US | disclosed |
| EP-3133080-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2017-02-22 | — | — | EP | disclosed |
| EP-2689033-B1 | DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS | UNIV CORNELL (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20170020996-A1 | ENZYMATIC DEBRIDEMENT THERAPY FOR ABNORMAL CELL PROLIFERATION | LIVINGSTON JAMES A (US) | 2017-01-26 | — | — | US | disclosed |
| US-9545452-B2 | Biomineral and metal binding liposomes, their synthesis, and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-01-17 | — | — | US | disclosed |
| US-20170008975-A1 | Anti-Tissue Inhibitor of Metalloproteinase-4 (Timp-4) Antibodies and Methods of Use Thereof | LANKENAU INST MEDICAL RES (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2016210365-A2 | CONSTRUCTS TARGETING NY-ESO-1 PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-9522164-B2 | Disulfide chemotherapeutic agents and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160339103-A1 | Functional Micelles for Hard Tissue Targeted Delivery of Chemicals | BOARD OF REGENTS OF THE UNIV OF NEBRASKIA (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016187585-A1 | DEIMMUNIZED LINKER AND METHODS OF USE | VIVENTIA BIO INC. (CA) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187571-A2 | HER2 IMMUNOTOXINS AND METHODS OF USING THE SAME | VIVENTIA BIO INC. (CA) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016182957-A1 | CONSTRUCTS TARGETING HPV16-E7 PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160318970-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2016-11-03 | — | — | US | disclosed |
| WO-2016161390-A1 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9441221-B2 | Compositions and methods for gene silencing | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2016133860-A1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160237164-A1 | ANTI-EPCAM ANTIBODIES AND METHODS OF USE | VIVENTIA BIO INC. (CA) | 2016-08-18 | — | — | US | disclosed |
| CN-105853445-A | DRUG DELIVERY DEVICE EMPLOYING WICKING RELEASE WINDOW | 橡冠科学研究院 | 2016-08-17 | — | — | CN | disclosed |
| EP-3052525-A1 | ANTI-EPCAM ANTIBODIES AND METHODS OF USE | Viventia Bio Inc. (CA) | 2016-08-10 | — | — | EP | disclosed |
| WO-2016118568-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116760-A2 | INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118730-A1 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-2231689-B1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2016-07-20 | — | — | EP | disclosed |
| US-20160199507-A1 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | UNIVERSITY OF ZURICH (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-2242359-B1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIV STRASBOURG (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160136093-A9 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS | UNIV NORTH CAROLINA (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136297-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2016-05-05 | — | — | US | disclosed |
| CN-101990399-B | Synthetic as the RALs of therapeutic agent | UNIVERSITE DE STRASBOURG (FR) | 2016-05-04 | — | — | CN | disclosed |
| US-9321800-B2 | 7-deazapurine nucleosides for therapeutic uses | GILEAD SCIENCES, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| CN-103747765-B | Drug delivery device employing wicking release window | OAK CREST INSTITUTE OF SCIENCE (US) | 2016-04-06 | — | — | CN | disclosed |
| US-9289505-B2 | Compositions and methods for delivering nucleic acid molecules and treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2016-03-17 | — | — | US | disclosed |
| US-20160060352-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | VIVENTIA BIO INC. (CA) | 2016-03-03 | — | — | US | disclosed |
| EP-2986324-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | Viventia Bio Inc. (CA) | 2016-02-24 | — | — | EP | disclosed |
| US-9266946-B2 | Targeting ABCB5 for cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9259484-B2 | Methods for treating cancer using an immunotoxin | UNIVERSITY OF ZURICH (CH) | 2016-02-16 | — | — | US | disclosed |
| EP-2473529-B1 | CLEC14A INHIBITORS | CANCER REC TECH LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-9255148-B2 | CLEC14A inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-02-09 | — | — | US | disclosed |
| US-20160030346-A1 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS | UNIV NORTH CAROLINA (US) | 2016-02-04 | — | — | US | disclosed |
| US-9248110-B2 | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis | LEHRER STEVEN (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2015200790-A2 | COMPOSITIONS AND METHODS TO REGULATE RENALASE IN THE TREATMENT OF DISEASES AND DISORDERS | YALE UNIVERSITY (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015179239-A1 | COMPOSITIONS AND METHODS TO INHIBIT ESTROGEN RECEPTOR BETA FOR THE TREATMENT OF RENAL CELL CARCINOMA | UNIVERSITY OF ROCHESTER (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015168614-A2 | POLYMER COMPOSITIONS OF HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9175352-B2 | Distinguishing benign and malignant indeterminate thyroid lesions | CORNELL UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2927322-A1 | Tumor specific antibody | Viventia Bio Inc. (CA) | 2015-10-07 | — | — | EP | disclosed |
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2015-08-06 | — | — | US | disclosed |
| WO-2015116689-A1 | ANTI-TISSUE INHIBITOR OF METALLOPROTEINASE-4 (TIMP-4) ANTIBODIES AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150203588-A1 | Cancer Biomarkers and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-23 | — | — | US | disclosed |
| US-20150197575-A1 | TUMOR SPECIFIC ANTIBODY | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2015-07-16 | — | — | US | disclosed |
| US-9078823-B2 | Compositions and methods for gene silencing | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2155248-B1 | TARGETING ABCB5 FOR CANCER THERAPY | BRIGHAM & WOMENS HOSPITAL (US) | 2015-06-10 | — | — | EP | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-20150147274-A1 | ANTIBODIES AGAINST HGF - RECEPTOR AND USES | CANCER REC TECH LTD (GB) | 2015-05-28 | — | — | US | disclosed |
| US-20150132317-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2015-05-14 | — | — | US | disclosed |
| US-20150125387-A1 | DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS | UNIV CORNELL (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150099796-A1 | Compositions and Methods for Gene Silencing | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-04-09 | — | — | US | disclosed |
| WO-2015048901-A1 | ANTI-EPCAM ANTIBODIES AND METHODS OF USE | VIVENTIA BIO INC. (CA) | 2015-04-09 | — | — | WO | disclosed |
| CN-104497084-A | Novel 7-deazapurine Nucleosides For Therapeutic Uses | ACAD OF SCIENCE CZECH REPUBLIC | 2015-04-08 | — | — | CN | disclosed |
| US-8999334-B2 | Antibody conjugates against variant NFKBIB and uses thereof | VIVENTIA BIO INC. (CA) | 2015-04-07 | — | — | US | disclosed |
| US-8969540-B2 | Tumor specific antibody | VIVENTIA BIO INC. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8945829-B2 | Distinguishing benign and malignant indeterminate thyroid lesions | CORNELL UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2829283-A1 | Methods for treating cancer using an immunotoxin | Universität Zürich (CH) | 2015-01-28 | — | — | EP | disclosed |
| EP-1766017-B1 | TUMOR SPECIFIC ANTIBODY | VIVENTIA BIO INC (CA) | 2015-01-21 | — | — | EP | disclosed |
| CN-102459300-B | Novel 7-deazapurine nucleosides for therapeutic use | ACAD OF SCIENCE CZECH REPUBLIC | 2014-12-10 | — | — | CN | disclosed |
| US-20140356287-A1 | PLOD2 as a Target of Intervention for Sarcoma Metastasis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2014166002-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | VIVENTIA BIO INC. (CA) | 2014-10-16 | — | — | WO | disclosed |
| US-20140302031-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2785741-A1 | ANTIBODIES AGAINST HGF - RECEPTOR AND USES | Cancer Research Technology Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296834-A1 | DRUG DELIVERY DEVICE EMPLOYING WICKING RELEASE WINDOW | OAKCREST INSTITUTE OF SCIENCE (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2382990-B1 | Methods for treating cancer using an immunotoxin | UNIV ZUERICH (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-20140178417-A1 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | UNIVERSITY OF ZURICH (CH) | 2014-06-26 | — | — | US | disclosed |
| US-8754045-B2 | Enzymatic debridement therapy for abnormal cell proliferation | GETAHOUN, ALEX | 2014-06-17 | — | — | US | disclosed |
| CN-103747765-A | Drug delivery device employing wicking release window | OAK CREST INST OF SCIENCE | 2014-04-23 | — | — | CN | disclosed |
| US-8697075-B2 | Cancer specific antibody and cell surface proteins | VIVENTIA BIO INC. (CA) | 2014-04-15 | — | — | US | disclosed |
| US-8697072-B2 | Targeting ABCB5 for cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140099261-A1 | DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS | CORNELL UNIVERSITY (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140079812-A1 | Disulfide Chemotherapeutic Agents and Methods of Use Thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2014022846-A1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Biocodex, Inc (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030218-A1 | Treatment And Screening | IMPERIAL INNOVATIONS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20130344076-A1 | ANTIBODY CONJUGATES AGAINST VARIANT NFKBIB AND USES THEREOF | VIVENTIA BIO INC. (CA) | 2013-12-26 | — | — | US | disclosed |
| US-8586636-B2 | Disulfide chemotherapeutic agents and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130302257-A1 | Compositions and Methods for Delivering Nucleic Acid Molecules and Treating Cancer | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130274142-A1 | Cell Co-Culture Systems and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2644205-A1 | Targeting ABCB5 for cancer therapy | The Brigham and Women's Hospital, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8545840-B2 | Methods for treating cancer using an immunotoxin | UNIVERSITY OF ZURICH (CH) | 2013-10-01 | — | — | US | disclosed |
| EP-2421879-B1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2013-09-04 | — | — | EP | disclosed |
| CN-101917976-B | Disulfide chemotherapeutic agents and methods of use thereof | LANKENAU INST MEDICAL RES | 2013-08-28 | — | — | CN | disclosed |
| US-20130217865-A1 | Tumor Specific Antibody | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130195964-A1 | Compositions and Methods for the Treatment of Cancer | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130177598-A1 | DISCRETE SIZE AND SHAPE SPECIFIC PHARMACEUTICAL ORGANIC NANOPARTICLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130171133-A1 | CANCER METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| US-20130150317-A1 | COMPOUNDS FOR THE TREATMENT OF RENAL CELL CARCINOMA | MYROVLYTIS TECHNOLOGY VENTURES LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2013079973-A1 | ANTIBODIES AGAINST HGF - RECEPTOR AND USES | DI CARA DANIELLE MARIE (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-8455205-B2 | Metalloproteinase 9 binding proteins | DYAX CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130137749-A1 | Compositions and Methods for Gene Silencing | SILAGENE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8426561-B2 | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof | VIVENTIA BIO INC. (CA) | 2013-04-23 | — | — | US | disclosed |
| EP-1833968-B1 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS | VIVENTIA BIOTECHNOLOGIES INC (CA) | 2013-04-17 | — | — | EP | disclosed |
| WO-2013034933-A1 | ANTI DDR1 ANTIBODIES, THEIR USES AND METHODS IDENTIFYING THEM | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-03-14 | — | — | WO | disclosed |
| US-8383117-B2 | CD44E tumor specific antibody | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| WO-2013025936-A1 | DETECTION AND TREATMENT OF METASTATIC DISEASE | CORNELL UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-2558114-A2 | CANCER METHODS | Imperial Innovations Limited (GB) | 2013-02-20 | — | — | EP | disclosed |
| US-20130039931-A1 | Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof | VIVENTIA BIO INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| EP-1894131-B1 | METHODS AND SYSTEMS FOR PREDICTING CANCER OUTCOME | H LEE MOFFITT CANCER CT & RES (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130004436-A1 | Compositions and Methods of Treating and Preventing Lung Cancer and Lymphangioleiomyomatosis | LEHRER STEVEN (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130004425-A1 | Biomineral and Metal Binding Liposomes, Their Synthesis, and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-01-03 | — | — | US | disclosed |
| US-8343941-B2 | Compositions and methods for gene silencing | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2536404-A1 | COMPOUNDS FOR THE TREATMENT OF RENAL CELL CARCINOMA | Myrovlytis Technology Ventures Limited (GB) | 2012-12-26 | — | — | EP | disclosed |
| EP-2533764-A1 | BIOMINERAL AND METAL BINDING LIPOSOMES, THEIR SYNTHESIS, AND METHODS OF USE THEREOF | The Board of Regents of the University of Nebraska (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012170578-A1 | DRUG DELIVERY DEVICE EMPLOYING WICKING RELEASE WINDOW | OAK CREST INSTITUTE OF SCIENCE (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-102811707-A | Biomineral and metal binding liposomes, their synthesis, and methods of use thereof | UNIV NEBRASKA | 2012-12-05 | — | — | CN | disclosed |
| US-8318472-B2 | Optimized nucleic acid sequences for the expression of VB4-845 | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20120276000-A1 | CLEC14A INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-8273550-B2 | Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2012-09-25 | — | — | US | disclosed |
| WO-2012093258-A2 | TREATMENT AND SCREENING | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-07-12 | — | — | WO | disclosed |
| EP-2473529-A1 | CLEC14A INHIBITORS | Cancer Research Technology Limited (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20120128723-A1 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2012-05-24 | — | — | US | disclosed |
| EP-2454011-A2 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS | The University of North Carolina At Chapel Hill (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120114554-A1 | Engineered Aerosol Particles, And Associated Methods | LIQUIDIA TECHNOLOGIES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120072124-A1 | GENES ASSOCIATED WITH PROGRESSION AND RESPONSE IN CHRONIC MYELOID LEUKEMIA AND USES THEREOF | ROSETTA INPHARMATICS, LLC | 2012-03-22 | — | — | US | disclosed |
| WO-2012031293-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2421879-A2 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. (CZ) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012024396-A2 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACID MOLECULES AND TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8093226-B2 | Cytostatic 7-deazapurine nucleosides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2012-01-10 | — | — | US | disclosed |
| US-8084576-B2 | Cancer associated glucose transporter 8 variant | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2011-12-27 | — | — | US | disclosed |
| US-8080531-B2 | Methods for modulating checkpoint activation through TopBP1 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110300157-A1 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | DYAX CORP. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011128701-A2 | CANCER METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130677-A1 | INHIBITORS OF CANCER STEM CELLS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011115988-A1 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING LUNG CANCER | LEHRER STEVEN (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110229418-A1 | Compositions and Methods of Treating and Preventing Lung Cancer | LEHRER STEVEN | 2011-09-22 | — | — | US | disclosed |
| US-20110217365-A1 | Compositions and Methods for Gene Silencing | SILAGENE, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-8014957-B2 | Genes associated with progression and response in chronic myeloid leukemia and uses thereof | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2011101677-A1 | COMPOUNDS FOR THE TREATMENT OF RENAL CELL CARCINOMA | MYROVLYTIS TECHNOLOGY VENTURES LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
| US-20110206691-A1 | Methods and Compositions for Treating Neuroblastoma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2011-08-25 | — | — | US | disclosed |
| WO-2011097563-A1 | BIOMINERAL AND METAL BINDING LIPOSOMES, THEIR SYNTHESIS, AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110171144-A1 | Functional Micelles for Hard Tissue Targeted Delivery of Chemicals | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2011-07-14 | — | — | US | disclosed |
| US-20110165149-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2313101-A1 | FUNCTIONAL MICELLES FOR HARD TISSUE TARGETED DELIVERY OF CHEMICALS | The Board of Regents of the University of Nebraska (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7928202-B2 | Targeting ABCB5 for cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101990399-A | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIV STRASBOURG | 2011-03-23 | — | — | CN | disclosed |
| WO-2011027132-A1 | CLEC14A INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110046002-A1 | Seven Gene Breast Cancer Predictor | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-02-24 | — | — | US | disclosed |
| CN-101970498-A | Antibodies against cancer-associated epitopes of variant HnRNPG and uses thereof | VIVENTIA BIOTECH INC | 2011-02-09 | — | — | CN | disclosed |
| WO-2011008737-A2 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100324133-A1 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders | LIOTTA DENNIS C | 2010-12-23 | — | — | US | disclosed |
| US-20100322919-A1 | Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2010-12-23 | — | — | US | disclosed |
| EP-2262530-A1 | METALLOPROTEINASE 12 BINDING PROTEINS | Dyax Corp. (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2262840-A2 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | Dyax Corp. (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2262529-A2 | METALLOPROTEINASE 9 BINDING PROTEINS | Dyax Corp. (US) | 2010-12-22 | — | — | EP | disclosed |
| CN-101925612-A | Antibodies against epitopes of cancer-associated NFKBIB variants and uses thereof | VIVENTIA BIOTECH INC | 2010-12-22 | — | — | CN | disclosed |
| CN-101917976-A | Disulfide chemotherapeutic agents and application process thereof | LANKENAU INST MEDICAL RES | 2010-12-15 | — | — | CN | disclosed |
| US-20100303814-A1 | Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof | VIVENTIA BIO INC. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100298412-A1 | Disulfide Chemotherapeutic Agents and Methods of Use Thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2010-11-25 | — | — | US | disclosed |
| US-20100284915-A1 | GENES ASSOCIATED WITH CHEMOTHERAPY RESPONSE AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2010121576-A2 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2010-10-28 | — | — | WO | disclosed |
| EP-2242359-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | Universite De Strasbourg (FR) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267086-A1 | Optimized Nucleic Acid Sequences For The Expression of VB4-845 | VIVENTIA BIO INC. (CA) | 2010-10-21 | — | — | US | disclosed |
| EP-2240460-A2 | BRANCHED DIEPOXIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Emory University (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100255999-A1 | Cell Co-Culture Systems and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100254982-A1 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS | VIVENTIA BIO INC. (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20100249039-A1 | Methods for Treating Cancer Using an Immunotoxin | UNIVERSITY OF ZURICH (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2231689-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2010-09-29 | — | — | EP | disclosed |
| US-7795389-B2 | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2225277-A1 | ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF | Viventia Biotech INC. (CA) | 2010-09-08 | — | — | EP | disclosed |
| US-20100215670-A1 | Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers | CIZEAU JEANNICK | 2010-08-26 | — | — | US | disclosed |
| EP-2215122-A1 | ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF | Viventia Biotech INC. (CA) | 2010-08-11 | — | — | EP | disclosed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| US-20100166731-A1 | Methods and Compositions for Treating Cancer | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100151031-A1 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| WO-2010065711-A1 | AN ABCB5 EPITOPE AND ANTIBODIES THERETO FOR THE TREATMENT OF CANCER | ADIMAB, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7705010-B2 | Use of minoxidil sulfate as an anti-tumor drug | CEDARS-SINAI MEDICAL CENTER (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2010045388-A2 | USE OF MMP-9 AND MMP-12 BINDING PROTEINS FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS | DYAX CORP. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2155248-A1 | TARGETING ABCB5 FOR CANCER THERAPY | The Brigham and Women's Hospital, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022481-A1 | Drug Carriers, Their Synthesis, and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| WO-2010006192-A1 | FUNCTIONAL MICELLES FOR HARD TISSUE TARGETED DELIVERY OF CHEMICALS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2010-01-14 | — | — | WO | disclosed |
| CN-101616920-A | The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101616921-A | The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | disclosed |
| US-20090311183-A1 | METALLOPROTEINASE 12 BINDING PROTEINS | DYAX CORP. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090311245-A1 | METALLOPROTEINASE 9 BINDING PROTEINS | DYAX CORP. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090297449-A1 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | DYAX CORP. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2115456-A2 | CELL CO-CULTURE SYSTEMS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009111450-A2 | METALLOPROTEINASE 9 BINDING PROTEINS | DYAX CORP. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111507-A1 | METALLOPROTEINASE 12 BINDING PROTEINS | DYAX CORP. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111508-A2 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | DYAX CORP. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. | 2009-08-13 | — | — | US | disclosed |
| WO-2009097397-A2 | METALLOPROTEINASE BINDING PROTEINS | DYAX CORP. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009089804-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2009-07-23 | — | — | WO | disclosed |
| EP-2079840-A1 | IMMUNOTOX N FUSIONS COMPRISING AN ANTIBODY FRAGMENT AND A PLANT TOXIN LINKED BY PROTEASE CLEAVABLE LINKERS | Viventia Biotech Inc. (CA) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009089285-A2 | BRANCHED DIEPOXIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | EMORY UNIVERSITY (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009067800-A1 | ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT NFKBIB AND USES THEREOF | VIVENTIA BIOTECH INC. (CA) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009067611-A1 | SEVEN GENE BREAST CANCER PREDICTOR | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090117117-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009052628-A1 | ANTIBODIES AGAINST A CANCER-ASSOCIATED EPITOPE OF VARIANT HNRNPG AND USES THEREOF | VIVENTIA BIOTECH INC. (CA) | 2009-04-30 | — | — | WO | disclosed |
| US-20090098111-A1 | Methods for modulating checkpoint activation through TopBP1 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009044158-A2 | INHIBITORS AND USES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044153-A2 | INHIBITORS AND USES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009039630-A1 | OPTIMIZED NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF VB4-845 | VIVENTIA BIOTECH INC. (CA) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009022104-A1 | FASCAPLYSIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | DE MONTFORT UNIVERSITY (GB) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048179-A1 | USE OF 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER OF ABNORMAL BRAIN TISSUE AND THE BLOOD-TUMOR BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080286239-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008127656-A1 | TARGETING ABCB5 FOR CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008118861-A2 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008106503-A2 | DISCRETE SIZE AND SHAPE SPECIFIC PHARMACEUTICAL ORGANIC NANOPARTICLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207657-A1 | Use Of Minoxidil Sulfate As An Anti-Tumor Drug | CEDARS-SINAI MEDICAL CENTER (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095165-A2 | CELL CO-CULTURE SYSTEMS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188480-A1 | Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier | CEDARS-SINAI MEDICAL CENTER (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008063229-A2 | ENZYMATIC DEBRIDEMENT THERAPY FOR ABNORMAL CELL PROLIFERATION | LIVINGSTON JAMES A (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119685-A1 | Methods for modulating checkpoint activation through TopBP1 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008052322-A1 | IMMUNOTOXΓN FUSIONS COMPRISING AN ANTIBODY FRAGMENT AND A PLANT TOXIN LINKED BY PROTEASE CLEAVABLE LINKERS | VIVENTIA BIOTECH INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| EP-1850663-A4 | USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG | CEDARS SINAI MEDICAL CENTER (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1894131-A2 | METHODS AND SYSTEMS FOR PREDICTING CANCER OUTCOME | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20080044459-A1 | Enzymatic debridement therapy for abnormal cell proliferation | GETAHOUN, ALEX | 2008-02-21 | — | — | US | disclosed |
| WO-2008005281-A2 | GENES ASSOCIATED WITH CHEMOTHERAPY RESPONSE AND USES THEREOF | ROSETTA INPHARMATICS LLC (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070292441-A1 | Tumor Specific Antibody | VIVENTIA BIOTECH INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| EP-1850663-A2 | USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG | CEDARS-SINAI MEDICAL CENTER (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1850852-A2 | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER | Cedars-Sinai Medical Center (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1848717-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Topotarget A/S (DK) | 2007-10-31 | — | — | EP | disclosed |
| US-20070244042-A1 | Antagonizing TGF-beta activity with various ectodomains of TGF-beta receptors used in combination or as fusion proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-18 | — | — | US | disclosed |
| WO-2007104999-A1 | ANTI-CANCER THERAPY | NORWEGIAN RADIUM HOSPITAL RESEARCH FOUNDATION (NO) | 2007-09-20 | — | — | WO | disclosed |
| EP-1833968-A1 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS | Viventia Biotech Inc. (CA) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007097934-A2 | METHODS AND COMPOSITIONS FOR USING ERYTHROCYTES AS CARRIERS FOR DELIVERY OF DRUGS | ELUSYS THERAPEUTICS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070196366-A1 | Methods for treating cancer using an immunotoxin | UNIVERSITY OF ZURICH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070154931-A1 | Genes associate with progression and response in chronic myeloid leukemia and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070122379-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| EP-0969720-B1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI INC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007041453-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ROSETTA INPHARMATICS LLC (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1766017-A1 | TUMOR SPECIFIC ANTIBODY | Viventia Biotech Inc. (CA) | 2007-03-28 | — | — | EP | disclosed |
| US-20070014768-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-7157079-B2 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060280748-A1 | Plasma or serum fraction for treatment or prevention of abnormal cell proliferation | BUCKHEIT ROBERT W JR | 2006-12-14 | — | — | US | disclosed |
| US-7144917-B2 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006116381-A2 | PLASMA OR SERUM FRACTION FOR TREATMENT OR PREVENTION OF ABNORMAL CELL PROLIFERATION | IMQUEST BIOSCIENCES, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006093507-A2 | METHODS AND SYSTEMS FOR PREDICTING CANCER OUTCOME | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060195269-A1 | Methods and systems for predicting cancer outcome | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-31 | — | — | US | disclosed |
| WO-2006091542-A2 | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091587-A2 | USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG | CEDARS-SINAI MEDICAL CENTER (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006085219-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006066408-A1 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS | VIVENTIA BIOTECH INC. (CA) | 2006-06-29 | — | — | WO | disclosed |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | QLT USA, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1780631-A | anticancer phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1635868-A1 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | Zangemeister-Wittke, Uwe (CH) | 2006-03-22 | — | — | EP | disclosed |
| EP-1622540-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005121341-A1 | TUMOR SPECIFIC ANTIBODY | VIVENTIA BIOTECH INC. (CA) | 2005-12-22 | — | — | WO | disclosed |
| US-20050227266-A1 | Biomarker:compound correlations in cancer diagnosis and therapy | APPLIED GENOMICS, INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1309579-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES | UNIV WAYNE STATE (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050181385-A1 | Microarrays; kits; genes confer drug resistance/sensitivity; anticancer agents | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| US-20050142112-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050096370-A1 | Method for inhibiting tumor angiogenesis and tumor growth | BIZBIOTECH CO., LTD. | 2005-05-05 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20050080239-A1 | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease | THE SCRIPPS RESEARCH INSTITUTE | 2005-04-14 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050004010-A1 | Cobalamin conjugates useful as imaging agents and as antitumor agents | MAYO FOUNDATION FOR MEDICAL EDUCATION | 2005-01-06 | — | — | US | disclosed |
| US-20040235736-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004096271-A1 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | ZANGEMEISTER-WITTKE UWE (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004091648-A1 | METHOD FOR INHIBITING TUMOR ANGIOGENESIS AND TUMOR GROWTH | HIF BIO INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040198798-A1 | Method for inhibiting tumor angiogenesis and tumor growth | BIZBIOTECH CO., LTD. (KR) | 2004-10-07 | — | — | US | disclosed |
| WO-2004081196-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY | 2004-07-01 | — | — | US | disclosed |
| US-6747061-B2 | ADMINISTERING AN ANTIPROLIFERATIVE AGENT IN COMBINATION WITH A POTENTIATING EFFECTIVE AMOUNT OF A N- SUBSTITUTED DITHIOCARBAMATE ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ATHEROGENICS, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-0969720-A4 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6703415-B2 | EPOXIDES OR THIIRANE DERIVATIVES; TREATING OR PREVENTING CANCER, ANGIOGENESIS, ARTHRITIS, CONNECTIVE TISSUE DISEASE, CARDIOVASCULAR DISEASE, INFLAMMATION OR AUTOIMMUNE DISEASE; ANTIFERTILITY AGENTS | WAYNE STATE UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | ATHEROGENICS, INC. (US) | 2003-09-18 | — | — | US | disclosed |
| EP-1309579-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030064949-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | NIELSEN LORETTA (US) | 2003-04-03 | — | — | US | disclosed |
| US-20030060434-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | NIELSEN LORETTA (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1282445-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | Atherogenics, Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002080986-A1 | AUTOANTIBODIES TO GLUCOSE-6-PHOSPHATE ISOMERASE AND THEIR PARTICIPATION IN AUTOIMMUNE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020146753-A1 | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease | SCRIPPS RESEARCH INSTITUTE, THE | 2002-10-10 | — | — | US | disclosed |
| EP-1231942-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AGENTS AND AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-08-21 | — | — | EP | disclosed |
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | UNITED STATES GOVERNMENT SECRETARY OF THE ARMY, THE | 2002-03-28 | — | — | US | disclosed |
| WO-2001092244-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001079164-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | ATHEROGENICS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001028592-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AGENTS AND AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000062075-A1 | UBIQUITIN CROSS-REACTIVE PROTEIN AS A PROGNOSTIC MARKER FOR TUMOR CELL CHEMOSENSITIVITY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6057348-A | INHIBITOR OF CELL GROWTH AND MITOSIS | OREGON STATE UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0969720-A2 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035554-A2 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| US-4826964-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0131285-B1 | ENAMINE DERIVATIVES OF DAUNORUBICIN AND ADRIAMYCINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | POLITECHNIKA GDANSKA (PL) | 1987-11-04 | — | — | EP | disclosed |
| US-4585859-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1986-04-29 | — | — | US | disclosed |
| US-4464529-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1984-08-07 | — | — | US | disclosed |
| US-4314054-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1982-02-02 | — | — | US | disclosed |
| US-4177264-A | ANITCARCINOGENIC AGENTS | SRI INTERNATIONAL (US) | 1979-12-04 | — | — | US | disclosed |
| US-4177264-A | ANITCARCINOGENIC AGENTS | SRI INTERNATIONAL (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324133-A1 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders | HPGDS, LTB4R2, TNF | S100A4 2424/4885PAX8 2098/4885HSP90AA1 2492/4885 |
| US-20100151031-A1 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE | CD47, CD69, ICOS | S100A4 3168/4885PAX8 3420/4885HSP90AA1 2199/4885 |
| US-20180250418-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | S100A4 1213/4885PAX8 1609/4885HSP90AA1 3272/4885 |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | S100A4 1785/4885PAX8 3049/4885HSP90AA1 431/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | S100A4 1418/4885PAX8 625/4885HSP90AA1 4573/4885 |
| US-10022325-B2 | Compositions and methods for the treatment of cancer | TP53, HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | S100A4 45/4885PAX8 2603/4885HSP90AA1 841/4885 |
| US-20050181385-A1 | Microarrays; kits; genes confer drug resistance/sensitivity; anticancer agents | TPX2, TSSK6, MKNK2 | S100A4 2005/4885PAX8 2419/4885HSP90AA1 988/4885 |
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | S100A4 3869/4885PAX8 1244/4885HSP90AA1 4552/4885 |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | S100A4 1677/4885PAX8 1232/4885HSP90AA1 2175/4885 |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | MMP12, MMP1, MMP3 | S100A4 1132/4885PAX8 1908/4885HSP90AA1 1193/4885 |
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | KHK, GCK, FN3K | S100A4 3555/4885PAX8 3686/4885HSP90AA1 3077/4885 |
| US-20090311245-A1 | METALLOPROTEINASE 9 BINDING PROTEINS | DNASE1L3, MMP10, MMP25 | S100A4 302/4885PAX8 2079/4885HSP90AA1 538/4885 |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | S100A4 1213/4885PAX8 1609/4885HSP90AA1 3272/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-20100022481-A1 | Drug Carriers, Their Synthesis, and Methods of Use Thereof | ABCB1, ABCG2, CES2 | S100A4 1408/4885PAX8 3767/4885HSP90AA1 1271/4885 |
| US-20090297449-A1 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | MMP10, MMP25, MMP2 | S100A4 306/4885PAX8 2327/4885HSP90AA1 528/4885 |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-20210361741-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL PEPTIDES | GJA1, GJB2, CNTN1 | S100A4 942/4885PAX8 1254/4885HSP90AA1 494/4885 |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | TPMT, TYMP, ENTPD5 | S100A4 3786/4885PAX8 1332/4885HSP90AA1 4450/4885 |
| US-11566075-B2 | Antibodies and related molecules and uses thereof | IGLV6-57, IGSF11, VSIG8 | S100A4 3334/4885PAX8 2751/4885HSP90AA1 2942/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | S100A4 688/4885PAX8 3973/4885HSP90AA1 1660/4885 |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | CDC25A, CCNB1, CCNE1 | S100A4 4248/4885PAX8 4392/4885HSP90AA1 1520/4885 |
| US-20080286239-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | VHL, TP53, BCOR | S100A4 364/4885PAX8 831/4885HSP90AA1 1256/4885 |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | S100A4 1213/4885PAX8 1609/4885HSP90AA1 3272/4885 |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | S100A4 1993/4885PAX8 2956/4885HSP90AA1 890/4885 |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP2B, TOP1 | S100A4 1805/4885PAX8 536/4885HSP90AA1 1867/4885 |
| US-20030064949-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | VHL, TP53, BCOR | S100A4 364/4885PAX8 831/4885HSP90AA1 1256/4885 |
| US-20040235736-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | VHL, TP53, BCOR | S100A4 364/4885PAX8 831/4885HSP90AA1 1256/4885 |
| US-20180362587-A1 | Compositions and Methods for Inhibiting CBP80 Binding to PGC1 Family of Co-Activators | CREB1, NCOA1, CREBBP | S100A4 1520/4885PAX8 563/4885HSP90AA1 46/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | S100A4 1213/4885PAX8 1609/4885HSP90AA1 3272/4885 |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | S100A4 1993/4885PAX8 2956/4885HSP90AA1 890/4885 |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | S100A4 4673/4885PAX8 4829/4885HSP90AA1 1/4885 |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | S100A4 1993/4885PAX8 2956/4885HSP90AA1 890/4885 |
| US-20130195964-A1 | Compositions and Methods for the Treatment of Cancer | TP53, HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | S100A4 45/4885PAX8 2603/4885HSP90AA1 841/4885 |
| US-20140079812-A1 | Disulfide Chemotherapeutic Agents and Methods of Use Thereof | MGMT, PDIA5, GPX4 | S100A4 993/4885PAX8 1632/4885HSP90AA1 374/4885 |
| US-20190085082-A1 | ANTIBODIES AND RELATED MOLECULES AND USES THEREOF | IGLV6-57, IGSF11, VSIG8 | S100A4 3334/4885PAX8 2751/4885HSP90AA1 2942/4885 |
| US-20200316233-A1 | RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF | FOLH1, SSTR4, SLC18A2 | S100A4 2598/4885PAX8 2642/4885HSP90AA1 1139/4885 |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | S100A4 3389/4885PAX8 2825/4885HSP90AA1 2083/4885 |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | S100A4 2408/4885PAX8 3330/4885HSP90AA1 2322/4885 |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | S100A4 4054/4885PAX8 2790/4885HSP90AA1 1077/4885 |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | S100A4 806/4885PAX8 4303/4885HSP90AA1 1098/4885 |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | HSP90AA1, HSP90AB1, HSP90AB2P | S100A4 4673/4885PAX8 4829/4885HSP90AA1 1/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | S100A4 2257/4885PAX8 3204/4885HSP90AA1 2012/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | S100A4 1849/4885PAX8 3464/4885HSP90AA1 1991/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | S100A4 2306/4885PAX8 1337/4885HSP90AA1 1300/4885 |
| US-20100303814-A1 | Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof | HNRNPLL, HNRNPAB, HNRNPUL2 | S100A4 1116/4885PAX8 2104/4885HSP90AA1 1618/4885 |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | S100A4 3081/4885PAX8 1699/4885HSP90AA1 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.